

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Limited Research Investigating the Value of MRI in Predicting Future Cognitive Morbidity in Survivors of Paediatric Brain Tumours: A Call to Action for Clinical Neuroimaging Researchers

Griffiths-King, Daniel¹, Delivett, Christopher¹, Peet, Andrew^{2,3}, Waite, Jane¹ & Novak, Jan¹

¹ Aston Institute of Health and Neurodevelopment, Aston University, Birmingham, B4 7ET, UK

² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK

³ Birmingham Women’s and Children’s Hospital NHS Foundation Trust, Institute of Child Health, Whittall Street, Birmingham B4 6NH, UK

Correspondence to: Dr Jan Novak (email: j.novak@aston.ac.uk)

ORCID

Griffiths-King, D. - <https://orcid.org/0000-0001-5797-9203>

Delivett, C. - NA

Peet, A. - NA

Waite, J. - <https://orcid.org/0000-0002-8676-3070>

Novak, J. - <https://orcid.org/0000-0001-5173-3608>

Abstract

Survivors of paediatric brain tumour patients are at high risk of cognitive morbidity. There is clinical benefit in being able to reliably predict, at the individual patient level, whether a patient will experience these difficulties or not, the degree of impairment, and the domains affected. Whilst established risk factors exist, quantitative analysis of MRI could provide added predictive value towards this goal, above and beyond existing clinical risk models. The current systematic review aims to answer the question “Do MRI markers predict future cognitive functioning in paediatric brain tumour survivors?”. Studies of paediatric brain tumour patients which test the value of MRI variables in predicting later neuropsychological outcomes were searched up to March 2024. Only included were studies where MRI scans were acquired at an earlier timepoint and used to predict a child's performance on cognitive tests at a later timepoint. Surprisingly few studies were identified by the systematic search process, but those that were identified specifically investigated MRI measures of cerebellar and white matter damage as features in predicting cognitive outcomes. Ultimately, the key finding of this review is that the current literature is limited. Those studies identified had small sample sizes and were rated as poor quality for the purposes of prediction. Therefore, current findings are at high risk of bias and thus the quality and conclusions are limited. Given the significant impact for this clinical population that predictive models would enable, the current review affirms the need for a ‘call to action’ for medical imaging researchers in paediatric neuro-oncology.

Keywords: MRI, neuropsychology outcomes, prediction, Brain Tumour, children

36 **Introduction**

37 *Individual Outcomes for Childhood Brain Tumour Patients*

38 Survival from cancer in childhood has seen great improvement in recent decades [1]. Consequently, there is an increasing
39 population of adult survivors [1, 2], with approximately 1 in 530 young adults between the ages of 20 and 39 being a survivor of
40 childhood cancer [3]. This is especially true in pediatric brain tumours, the most common solid tumours in children (roughly 20%)
41 [4], where survival is now estimated at around 95% for cerebellar pilocytic astrocytoma, and 60-80% for medulloblastoma [5-8].
42 Thus, there is an ever increasing need to focus on ensuring quality of life for the future of these children.

43 Many children with brain tumours experience neurocognitive effects at some point in their disease course, resulting in dysfunction
44 in domains of cognition, emotion, and behaviour. The estimated risk for children with brain tumours of having emotional,
45 psychosocial, and attention problems are 15%, 12% and 12% respectively, according to a recent meta-analysis [9]. Even at 10-
46 year survival, these patients still demonstrate neuropsychological and psychosocial impairment across multiple domains [10].
47 Recent, large-scale, longitudinal studies have suggested an increased risk of continuing neurocognitive decline for these patients,
48 irrespective of treatment type [11]. Performance over time demonstrates an inability to acquire new skills and cognitive abilities
49 at the same rate as healthy peers, rather than a loss of previously acquired abilities [12]. This may explain why these difficulties
50 are likely to persist long-term and are non-transient. The number of post-cancer life-years is greater for pediatric rather than adult
51 survivors, and these years include important milestones such as education and interpersonal relationship development [13]. Long-
52 term difficulties could profoundly affect participation for these children, at home, school and later in the workplace, likely
53 resulting in poorer long-term educational and employment outcomes [14, 15]. This represents a persistent burden for patients,
54 families and healthcare systems [16]. Whilst survival must always be the utmost priority, research aimed at limiting cognitive
55 morbidity in this group is now needed to ensure likelihood of reaching their potential, despite their illness [17].

56 Whilst disease and treatment will inevitably place all pediatric brain tumour patients at some level of risk for poor cognitive
57 outcomes, knowing individualised risk, an estimate of the severity of difficulties and specific domains likely to be impacted, will
58 influence clinical practice. There is significant variability in outcomes at the individual patient-level, but this is currently
59 understudied [16]. Person-centred analytical approaches across a large longitudinal sample of paediatric brain tumour patients,
60 show distinct classes / phenotypes with unique profiles in social, cognitive, and attentional difficulties over time [18], with similar
61 subgroups identified in cross-sectional data [19]. Percentages of individuals scoring in the ‘impaired range’ was between 28-55%
62 across domains in a recent longitudinal study, at around 6yrs post diagnosis [11] – highlighting, within a ‘cutoff’ driven
63 framework of cognitive impairment, the presence of a classification task for identifying/labelling individual cases of impairment.
64 Thus, there is scope for developing individualised models of risk and resilience, which hold predictive validity.

55 *Clinical Benefits from Prediction of Cognitive Outcomes*

56 Prediction of individual-level neurocognitive outcomes would enable timely and tailored input from school and allied health
57 services, promoting outcomes for these children, with limited healthcare resources being efficiently prioritised for those most at
58 risk. It would also help healthcare professionals counsel and educate patients for these difficulties and help reduce uncertainty
59 about the future for families. Individual models of risk would also impact treatment planning. In children where treatment of their
60 brain tumour is more difficult, adjuvant therapy may include radiotherapy, which is known to have significant impact on a child’s
61 neurodevelopment. This is due to brain injury from the primary and secondary effects of radiotherapy, especially in paediatrics
62 where there is specific vulnerability (e.g., due to younger children not yet having reached peak myelin maturity) [20, 21]. Whilst
63 developments in treatment have mitigated some neurocognitive toxicity (e.g. proton beam radiotherapy [22]), there is still need for
64 clinicians to navigate treatment decisions in terms of risk to QoL based upon known disease and age related risk factors [20, 21].
65 More accurate prediction of individual-level risk of cognitive morbidity (even across domain and severity), would enable
66 clinicians to further adapt and personalise treatment schedules with a greater focus on risk to quality-of-life whilst maintaining
67 treatment efficacy [23]. Overall, there is clinical benefit for a range of patients in knowing individualised prediction of
68 neurocognitive outcomes, and developing these methods for deployment to a clinical setting.

69 *Predicting Cognitive Outcomes*

70 There are many established risk factors for poor long-term neuropsychological outcome that need to be understood to provide a
71 comprehensive risk profile at the individual child level [24]. Recent neurodevelopmental models based on known risk factors have
72 been proposed to explain outcomes for brain tumour survivors, specifically in medulloblastoma [25-27], taking into consideration
73 the complex disease-, treatment- and host-related factors that may influence these outcomes. Many aspects can result in
74 neurodevelopmental insults to the developing brain which may explain and underpin these neurobehavioral morbidities [28, 29]
75 and thus are significant risk factors for these poor outcomes [24]. These range from physical factors such as treatment effects (i.e.
76 resection and/or adjuvant therapy [20, 30]) and individual differences (e.g. age at diagnosis [30], cognitive reserve), but also
77 psychological factors (i.e. Early Childhood Adversity, threat exposure) and environmental factors (i.e. Socioeconomic Status
78 (SES) and social support) [28]. See [24] for a model of cognitive risk in pediatric brain tumour survivors. Essentially,
79 neurocognitive outcomes are complex and are dependent on several interacting factors [13].

30 Risk-based and exposure-related guidelines and models have been developed to manage these neurocognitive late-effects of
31 pediatric brain tumours [24, 31]. Neurobehavioral morbidities are predicted by clinical variables such as radiotherapy,
32 chemotherapy, neurosurgery, and parental education but less-so age at diagnosis, gender, or time since diagnosis [13, 14, 20, 32-
33 35]. A number of these complex risk factors can be either difficult to measure or qualitative in their assessment and therefore can
34 inform decisions but do not make individual predictions. The Neurological Predictor Scale (NPS) was designed as an ordinal scale
35 to quantitatively capture the cumulative effect of several risk factors on outcomes, and somewhat predicts IQ, adaptive
36 functioning and processing speed and working memory, at both short- and long-term follow-up [34, 36-39]. This cumulative
37 measure captures unique variance, above and beyond the individual predictors.

38 *MRI as a Novel Predictor of Outcomes*

39 This systematic review posits that magnetic resonance imaging (MRI) measures are likely to be a good proxy of the burden of
40 brain tumours and their treatment thus, are likely to be predictive of cognitive impairment at the individual patient-level.
41 Qualitative reporting of MRI does predict outcomes, with brainstem invasion, midline location of the tumour, and tumour type
42 predicting post-operative cerebellar mutism syndrome, a (typically) transient, neurological morbidity seen in this population [40].
43 Quantitative alterations to the brain's structure and function, specifically microstructural changes to the white matter (WM) of the
44 brain, during the developmental period, could be the common neuroanatomical substrate of poor neurocognitive outcomes [25,
45 27]. See [41] and [23] for a review of MRI in pediatric brain tumours. Recent successes and interest in using MRI to predict
46 neurodevelopmental outcomes in premature infants [42], or even decline in neurocognitive functioning in older adults [43]
47 highlights the potential opportunities offered by MRI. There is also a relative abundance of MRI data in these patients, acquired as
48 part of standard of care and most research protocols. Therefore, MRI is likely to provide highly relevant features which provide
49 'added-value' in predicting outcomes beyond clinical risk factors alone.

10 A key consideration, however, is the timing of the MRI used to predict these outcomes. The MRI used for prediction needs to be
11 early enough in the disease course and non-contemporaneous from the later, outcome of interest. There is currently no consensus
12 on the optimal timing of MRI with which to make such a prediction. This systematic review specifically investigates existing
13 literature using MRI scans, taken at any point in the disease course, to predict non-contemporaneous, later neuropsychological
14 outcomes in survivors of pediatric brain tumours.

15 Whilst there is existing literature of existing established clinical predictors of cognitive late effects in this population, this review
16 aims to assess studies using MRI as a predictive modality, with the goal of assessing whether quantitative analysis of MRI
17 provides 'added-value' in these risk models.

18 **Method**

19 We conducted this systematic review in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis
20 (PRISMA) guidelines [44], an overview of which is reported in Figure 1. Initially, a limited search of the Web of Science database
21 was undertaken in June 2022 for the purpose of refining the search terms. Due to the wide-ranging classifications of central
22 nervous system (CNS) tumours, as well as generic tumour-focussed terms, we also included terms pertaining to the most common
23 paediatric histological diagnoses accounting for 85% of total incidence rates (Central Brain Tumour Registry of United States,
24 2014-2018 [45]). Search terms can be found in supplemental materials. Based on our initial search, we pre-registered our review
25 protocol through the International Prospective Register of Systematic Reviews (PROSPERO) database (registration number
26 CRD42022343161).

27 A comprehensive search of Embase, MEDLINE, PsycINFO, Scopus and Web of Science was conducted in July 2022 using the
28 designed search, resulting in 8,632 records. Searches were rerun and results updated in March 2024, resulting in an additional 899
29 records. Alterations were made to the search terms for each database to account for differing Boolean operators (see Supplemental
30 Materials). Additionally, we also searched the Open Science Framework (OSF) preprints archive for relevant articles that had not
31 otherwise appeared as published texts in our main search. We included any longitudinal study concerning patients diagnosed with
32 a brain tumour before the age of 18, who had MRI data that clearly preceded an age-appropriate, standardised test of cognitive
33 ability (e.g., intellectual ability assessed with WISC-V [46]). Central to our main research aim, we included those studies that
34 explicitly reported an association between future cognitive outcomes based on prior MRI. Meta-analyses and literature reviews
35 that did not report new data were excluded, however, reference lists of relevant papers were searched for additional studies of
36 interest. Search results were not restricted by publication date but were limited to those written in English. In addition to our pre-
37 registered exclusion criteria, we also excluded patients with neurofibromatosis, tuberous sclerosis, or acute lymphoblastic
38 leukaemia as these were considered significant confounds for predicting cognitive outcomes. We also excluded non-peer reviewed
39 articles, such as conference abstracts and theses. Inclusion/exclusion criteria are further detailed in Table 1.

40

11

Table 1. Inclusion and exclusion criteria for identifying publications for the systematic review


Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none">• Primary CNS tumour• Diagnosis of pediatric brain tumour, between ages of 0-18• Must include brain MRI (of any modality) and age-appropriate, standardised neuropsychological evaluation.• MRI must precede neuropsychological testing, by any period of time.• Report analyses of an association between or prediction of, prospective cognition from MRI.• Written in English	<ul style="list-style-type: none">• Patient groups where CNS tumours may be present but secondary to other disease (i.e. NF1)• Case studies• Meta-analyses and systematic reviews• Pre-prints where subsequent publication is already included• Not written in English• Conference Abstracts and Theses

12

13 Identified records were first imported into MS Excel and duplicates removed. Following a short pilot, two independent reviewers
14 (CD + DGK) screened the titles and abstracts of all the identified papers against the inclusion criteria. Full texts of suitable papers
15 were subsequently retrieved and screened by both reviewers for final inclusion in the review. For completeness, the reference lists
16 and citations of those papers marked for inclusion were reviewed for additional studies that may have been missed. At each stage
17 of the process, disagreements were discussed until consensus was met. Per our pre-registration, data extraction was completed by
18 one reviewer (DGK), whilst a second reviewer evaluated data extraction of all papers for correctness (JN). The data extraction
19 tool was initially developed for this research protocol and was later refined based upon the findings of the search results. This was
20 not based on an existing tool, and items were selected based on discussion within the research team. Data from each study
21 included: (1) year of publication, (2) study aims and/or hypotheses, (3) study location (i.e., country, recruiting hospital), (4)
22 number of patients, (5) patient characteristics (i.e., years recruited, diagnoses, treatments, cognitive outcomes, age at
23 diagnosis/MRI/neuropsychological evaluation), and (6) statistical analyses.

24 We had initially registered our intention to assess the validity of the included studies using the Transparent Reporting of a
25 multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines; however, this was deemed unsuitable
26 given that none of the studies reported using predictive modelling in their approach. Instead, studies were reviewed (by DGK)
27 using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist [47, 48], a checklist for
28 assessing reporting quality specific to the domain of oncology. Whilst designed for marker/assay testing, the domain relevance
29 and prognostic nature renders this a relevant tool. We considered the MRI measures as the 'marker' under investigation and the
30 neuropsychological assessment as 'endpoints' for the purposes of the checklist.

1 Figure 1. PRISMA flow diagram (based on March 2024 Search)



33 Results

34 After reviewing titles and abstracts, 197 records were selected (see Fig1), and 188 full-text articles were assessed for eligibility.
35 Of those, five studies were included. Manual reference and citation checking of these selected articles (and identified literature
36 reviews deemed to be relevant), identified no additional studies. Detailed information about the included studies can be found in
37 Table 2.

38 Study characteristics and reporting quality

39 Many studies were excluded because the MRI did not precede neuropsychological assessment (for instance because of the
40 matched timepoints of neuroimaging acquisition and test assessment), thus not defining them as ‘predictive’ studies. In a small
41 number of cases, the text was ambiguous to the order of testing (i.e., [49-54]) but did not refer to prediction or other details
42 suggestive of the order, and thus were not included. For other studies, data including MRI which preceded a later neurocognitive
43 assessment existed, due to the inclusion of multiple timepoints, however it was ambiguous in the analyses of interest as to the time
44 points being referred to and so these studies were not included [55, 56].

45 For the selected studies, sample sizes were small and ranged between $n=7$ and $n=61$; altogether (notwithstanding dataset overlap)
46 only $n=118$ pediatric brain tumour patients and $n=37$ healthy controls were included across the reviewed studies. The most
47 common tumour type across studies was medulloblastoma ($n=96$), then astrocytoma ($n=17$) with relatively few ependymoma and
48 choroid plexus papilloma ($n=3$ & 1 respectively). Age at diagnosis across the studies ranged from 2.2 years to 15.6 (based on
49 ranges and inter quartile range (IQR)). All studies selected associative statistical approaches (i.e., correlational analyses), with
50 one also adopting a mediation approach.

51 Using the REMARK checklist, studies were assessed against each reporting item (*Item 1-20*), and here we report items where
52 reporting was limited across the studies (i.e. one or less studies reported the item). No studies gave a rationale for sample size
53 (*Item 9*, 0/5 studies), likely due to the limited samples in each study, however it was unclear as to whether these were the entirety
54 of eligible patients within the given timeframe (as only 1 study gave a full accounting of the flow of patients in the study, *Item 12*,
55 2/5 studies) In terms of “Analysis and presentation”, studies performed poorly for a number of items (*Item 15, 16, 18*, all 1/5
56 studies, and *Item 17* 0/5 with no studies completing the item to be reported). Firstly, only one study presented an effect size for the
57 predictive analysis (*Item 15*, 1/5 studies). Further, included studies did not conduct analysis of added value, including the MRI
58 marker and ‘standard prognostic variables’ which are established (*Item 17*, 0/5 studies) nor sensitivity analysis/validation although
59 one study confirmed statistical/theoretical assumptions (*Item 18*, 1/5 studies).

60 White Matter (WM) predictors

61 Of the studies assessed, three utilised diffusion tensor imaging (DTI) to image white matter as a predictor of outcomes. Liguoro et
62 al. measured the fractional anisotropy (FA) and volumetry of spinocerebellar (SC), dentorubrothalamic (DRTC) and
63 corticopontocerebellar tracts (frontopontocerebellar (FPC), parieto-pontocerebellar (PPC), occipitopontocerebellar (OPC), and
64 temporo-pontocerebellar (TPC)) [57]. Significant relationships were found between tracts relevant to cerebellar connectivity, and
65 the Developmental Neuropsychology Assessment (NEPSY) and full-scale IQ (FSIQ) measured approximately 5 months later [57].
66 Specifically, FSIQ correlated significantly with spherical and planar indices of the right PPC ($r=-1$, $p=0.017$ and $r=0.886$,
67 $p=0.033$), with increases to planar index and decreases in spherical index associated with IQ [57]. Liguoro et al. also found
68 significant correlations between specific fibre tract characteristics and tasks measuring attention, memory, sensorimotor, social
69 perception, and visuospatial processing domains. However, only visuospatial processing showed convergent validity with
70 significant correlations across two different tasks measuring this same domain [57]. In this study, the bilateral PPC and SC tracts
71 were most commonly correlated with the neuropsychology tasks [57].

72 Partanen et al., used MRI from the treatment period 3 months after diagnosis (including during and after treatment) to predict
73 change in intellectual functioning over a 36 month period after diagnosis. A significant reduction in FSIQ over time was found but
74 this was not related to diffusion measures (FA, mean diffusivity (MD), radial diffusivity (RD) and axial diffusivity (AD)) for the
75 cortical spinal tract (CST), inferior fronto-occipital fasciculus (IFOF), inferior longitudinal fasciculus (ILF), optic radiations (OR),
76 and uncinate fasciculus (UF) [58]. Partanen et al. did however show that declines over time in processing speed index, observed
77 only in a subgroup of patients experiencing local therapy (i.e., focal radiation) versus cranial spinal radiation, was predicted by
78 baseline anisotropy in left inferior fronto-occipital fascicle (IFOF), with lower FA being related to greater decline [58]. Neither
79 patient groups showed a difference in the left IFOF for diffusion measures compared to controls.

80 Riggs et al. [59] utilised chronically acquired MRI (approximately 5 years post diagnosis) investigated correlations between
81 whole brain WM volume, FA of both the left and right UF and the general memory index of the Childhood Memory Scale (CMS)
82 (in a subset of $n=10$ patients, outcomes measured between 2 and 19 months after MRI). Only FA of the left UF was significantly
83 related to memory ($R=.64$, $p=.045$), not the right uncinate fasciculus or total WM volume (as measured by structural MRI), with
84 increased FA related to increases in memory performance. The volume of the PPC tract also positively correlated with memory
85 performance ($R=.71$, $p=.045$) in Partanen’s study [58].

16 Wang et al. [60] used a high-dimensional mediation model to estimate microstructural damage to brain WM that mediates the
17 negative treatment effects craniospinal radiation has on declining working memory outcomes over a 36month period. Post-
18 treatment DTI was used to estimate FA tract-based spatial statistics (TBSS) across tracts within a white-matter atlas. Larger FA
19 was associated with better working memory outcome, across multiple WM tracts including the cerebral peduncle, corpus
20 callosum, splenium and corona radiata. Specifically, Wang et al [60] found that there was a significant negative mediation effect
21 of the WM microstructure between radiation treatment (average risk / lower dose vs high risk / higher dose) and the change in
22 working memory over 36 months. This study therefore demonstrated the causal effect of radiation-related damage to white matter
23 predicting long-term working memory in these children, accounting for around 43% of the overall impact of treatment on long-
24 term working memory decline.

25 Strength of correlational relationship between indices of white matter integrity and neuropsychological outcome were large
26 (according to Cohen's criteria) ranging from $|r|=.64$ - $|r|=1$. However, the very limited sample sizes ($n=10$ & $n=7$) from which
27 these were drawn gives reason for concern over the interpretation of these estimates.

28 **Grey Matter (GM) predictors**

29 In Riggs et. al., no correlation was found between total GM volume or left hippocampus with the general memory index of the
30 CMS, but the right hippocampal volume, measured at a chronic timepoint, showed significant positive correlation with memory
31 outcomes 2-19 months after MRI ($R=.71$, $p=.02$) [59]. It is important to note in this study, that the right hippocampus, rather than
32 the GM volume and left hippocampus, was significantly smaller in the patient group compared to healthy controls.

33 **Lesion predictors**

34 Zilli et. al. [61] used a lesion-symptom mapping approach, to investigate the overlap of lesions in children with versus without
35 psychological impairment. The lesions investigated were tumour lesions, frontal insertion of ventriculoperitoneal drainages and
36 ventricular volumes, as drawn on the T1w MRI. They found the greatest tumour lesion overlap and therefore greatest damage was
37 found in median cerebellar, specifically paravermal and vermal regions. Regions of interest for the lateral ventricles also
38 overlapped in impaired children, suggesting hydrocephalus as additional cause of future impairment.

39 **Meta-analysis**

70 Despite registering our intention, reviewed studies were not of sufficient quality to conduct any form of meta-analysis due to
71 varying measurement strategies, gaps in reported descriptive variables, and low power.

Table 2. Details of included studies

Reference	Study Variables				Medical Variables		
	Recruitment Hospital	Years of Recruitment	Number of participants	Healthy controls?	Age at Diagnosis	Tumour Type	Treatment
Zilli et al. [61]	Azienda Sanitaria Universitaria Integrata di Udine, Italy	2012-2019	7 (5 males, 2 females)	NA	Med. 5.3y (IQR 2.2-8.1)	PA n=5, MB n=2	Surgery (7, 100%), Radical surgery (7, 100%), CT (2, 29%), CRT (1, 14%), PT (1, 14%)
Partanen et al. [58]	Hospital for Sick Children, Alberta Childrens Hospital, British Columbia Childrens Hospital, Canada	2007-2011	CSR Group 12 (7 males, 5 females), Local therapy 10 (5 males, 5 females)	24 (12 males, 12 females), Mean age at testing 10.51y (range 5.81-14.93)	CSR Group: Mean 9.32y (sd 2.69, range 5.96-15.26), Local Group: Mean 9.59y (sd 3.62, range 5.77-15.63)	CSR group: MB n=12, Local group: Astrocytoma n=6, EP n=3, Choroid Plexus papilloma (4th Ventricle) n=1	CSR group: surgery (12), CSR (12) and focal radiation to tumour bed (12), chemotherapy (12), Local therapy group: surgery only (7), surgery and focal radiation to the tumour bed (3), chemotherapy (1).
Liguoro et al. [57]	NR	2013-2017	7 (4 males, 3 females)	NA	Med. 63 months (IQR 39-80)	PA n=5, MB n=2	Only surgery (5, 72%), Surgery + RT + CT (2, 28%)
Riggs et al. [59]	Hospital for Sick Children, Alberta Childrens Hospital, British Columbia Childrens Hospital, Canada	2007-2011	20 (13 males, 7 females)	13 (8 males, 5 females), Mean age at test 12.5y (range 8.1-17.2)	Mean 7.2y (range 4.3-12.8)	Recurrent Astrocytoma n=1, MB n=19	surgery (20, 100%), CRT (20, 100%), CT (NR)
Wang et al. [60]	NR	NR	AR Group 43 (29 males, 14 females); HR Group 18 (10 males, 8 females)	NA	AR Group: Mean 14.85yr (sd 4.54); HR Group: Mean 13.31 (sd 4.06)	MB n=61	CRT plus CT (AR Group: Lower CRT dosage (70%), HR Group: Higher CRT dosage (30%))

N.B. NA = Not Applicable, PA = Pilocytic Astrocytoma, MB = Medulloblastoma, CT = Chemotherapy, CRT = Cranial Radiation Therapy, PT = Proton Therapy, AR = Average Risk*, HR = High Risk*, NR = Not Reported, Med = Median, sd = standard deviation.

*Defined by the SJMB03 phase III risk-adapted trial (ClinicalTrials.gov identifier: NCT00085202)

2

3

Table 2. (cont.)

Reference	MRI Variables				Neuropsychology Variables			Statistical Variables	
	Age at MRI	MRI Timepoint	Sequence	MRI Measure	Age at Assessment	Measure	Time between MRI and Assessment	Statistical Approach	Statistic of association/prediction
Zilli et al. [61]	NR	Post-surgery	1.5T T1w, T2w, FLAIR	sMRI - VOI of i) lesion, ii) frontal insertion of VPS and iii) ventricular volume, achieved extent of resection.	Med. 7.3y (IQR 6.0-10.8)	NEPSY-II, BVL_4-12	Med. 5.0 months (IQR 0.0 - 11.0)	Lesion symptom mapping	NA
Partanen et al. [58]	CSR Group: Mean 9.59y (sd 2.66, range 6.27-15.41), Local Group: Mean 9.88y (sd 3.65, range 6.01-16.07)	During and Post-Treatment (3m post diagnosis)	1.5T T1w, DTI	dMRI - FA, MD, RD, AD	NR - Multiple assessment timepoints (3, 12, 24, and 36 months post diagnosis),	WISC-IV or WAIS-IV	NR - Multiple assessment timepoints (3, 12, 24, and 36 months post diagnosis),	Correlational analyses	Pearson's r
Liguoro et al. [57]	NR	NR (post-resection)	1.5T T1w, T2w, FLAIR, DTI	Fibre tract volume, FA, RA, SI, PI, LI (cerebellar connections)	Med. 88m (IQR 74.5-129.5)	NEPSY-II WISC-IV	Med. 5m (IQR 0-8.5)	Correlational analyses	Spearman's Rank
Riggs et al. [59]	NR	Chronic post treatment (5yr-post diagnosis)	1.5T T1w, DTI	Whole brain volumes, Uinate Fasciculus (FA), hippocampal volume.	NR	CMS	n=10 assessed, n=7 <2 months of MRI, n=3 <19 months of MRI	Correlational analyses	NR
Wang et al. [60]	NR	Post-CRT	DTI	Voxel-wise, Tract-Based Spatial Statistics measured with FA	NR	Working Memory score from WJ-III	NR – Assessment was change in score between baseline and 36m	Mediation/Correlational analyses	NR

N.B. PA = Pilocytic Astrocytoma, MB = Medulloblastoma, EP = Ependymoma, CT = Chemotherapy, CRT = Cranial Radiation Therapy, PT = Proton Therapy, NR = Not Reported, sMRI = structural MRI, dMRI = Diffusion MRI, VOI = Volume of Interest, FA = Fractional Anisotropy, MD = Medial Diffusivity, RD = Radial Diffusivity, AD = Axial Diffusivity, Med. = Median, BVL=Battery for the Assessment of Language in Children aged 4-12, WJ-III = Woodcock-Johnson III Tests of Cognitive Abilities, CMS = Children's Memory Scale, CSR=Cranial-Spinal Radiation, m = months, NA = Not applicable.

75 Discussion

76 Review of the State of Research

77 The current systematic review aimed to investigate existing literature using MRI to predict later, and non-contemporaneous
78 neuropsychological outcomes in children with brain tumours. No studies reviewed here set out the rationale for and/or aimed to
79 predict future outcomes using model development and validation approaches. The lack of scientific attention given to this topic is
80 surprising given the dearth of literature advocating for such research. The papers identified and reviewed here, did in fact conduct
81 analyses to this effect, but only due to the fortuitous nature of the selected timepoints, and intervals between the activities of MRI
82 scanning and neuropsychological testing. Despite an extensive search strategy, evidence with which to answer the current research
83 question was extremely limited, with the major finding being a severe lack of studies in this area. The primary result of the review
84 must therefore be viewed as a need for further research in this very important research area, with study designs that directly tackle
85 the need for outcome prediction in these cohorts.

86 The reason for this limited number of research studies is unclear. Whilst our systematic search strategy was extensive, there were
87 also difficulties in identifying papers due to poor reporting practices. For instance, in some studies, the timing of MRI in relation
88 to assessment was ambiguous or unclear [49-52, 56]. Another potential cause of limited research could be previous focus on
89 survival, where increasing survival rates are now placing a greater need for research on late effects. It is important to also consider
90 that neurocognitive effects are also only one of many potential late effects experienced by this population [62, 63].

91 Quantity of research in this area may also be impacted by the availability of clinical data with which to carry out this research. For
92 children with pediatric brain tumours, there is an abundance of clinical MRI, with medical imaging required for vital for tumour
93 detection and diagnosis, surgical and radiotherapy planning, and monitoring of treatment response and recurrence of disease. But
94 this is not necessarily echoed in access to neurocognitive assessment; testing is performed based upon clinical need or clinical trial
95 protocol. This potentially limits available retrospective datasets. This data also comes from a heterogeneous cohort, with these
96 children facing heterogeneous brain injuries as a result of their disease and treatment. Identifying homogenous patient groups
97 inevitably results in the smaller sample sizes seen in the current studies. Overall, these factors are liable to impact the quantity of
98 research studies in this field.

99 Whilst number of studies was limited, the quality of existing studies was also a significant limiting factor for the usefulness of
100 research studies in this area. In the reporting quality assessment (using the REMARK checklist [47, 48]) identified studies did not
101 meet important criteria for development of prognostic markers. Specifically, studies failed to conduct additional analyses
102 necessary for this development, such as sensitivity or 'added-value' analyses – although this was likely due to limited sample
103 sizes, therefore lacking statistical power necessary for these additional analyses. Studies are typically involving “retrospective,
104 monocentric study investigating a pediatric disease with low annual incidence” [61] however future work will require larger
105 sample sizes than those of the studies presented here. To note, the checklist also comments on several items pertaining to model
106 building and multivariate analyses, which were not conducted in the current studies.

107 Overall, the findings from the reviewed research are limited – they have limited sample sizes and are rated as low quality in terms
108 of prediction studies. Without proper validation and replication, the quality and impact of any conclusions must be viewed as
109 limited and/or potentially spurious. However, the findings are briefly discussed here in terms of wider literature. This should be
110 seen in the context of guiding hypothesis-driven future research and/or promoting future validation and/or replication of these
111 findings.

112 Summary of Findings of Reviewed Studies

113 *Cerebellar Damage:* Given common posterior fossa presentation in pediatric brain tumours, it is unsurprising that
114 multiple studies in this review a-priori selected regions of interest within cerebellar structures and related fibre projections from
115 this anatomical structure. Damage to these circuits predicted outcomes [57], with lesions to the median cerebellar regions common
116 in cognitively impaired patients [61]. Studies of contemporaneous MRI and neuropsychology measures have found similar.
117 Horská and colleagues [64] found a decrease in vermis volumes over a 6-month period were significantly related to radiation dose,
118 and final volume after this period related to neuropsychological measures of motor speed. Significant recent evidence suggests
119 that the posterior cerebellar lobes are key in maintain cognitive performance [65], and animal models suggest that intact cerebellar
120 activity is required to enable typical developmental trajectories of cognitive abilities (in mice) [66]. Essentially, the cerebellum
121 plays as an integral node in many distributed neural circuits that underpin multiple cognitive functions [67, 68]. Radical cerebellar
122 resection has also been associated with extensive WM microstructure changes across the brain [69]. Overall, it is unsurprising that
123 damage to cerebellar regions (through injury and treatment effects) may lead to and/or predict multiple cognitive morbidities.

124 *WM damage:* Riggs et al [59] argued that global measures of WM may be indicative of general injury and thus correlate
125 well with general ability, however, integrity of discrete tracts (such as the UF) may be a better predictor of specific cognitive
126 abilities – in this case memory. Previous reviews of cross-sectional research suggests a model where disorganised WM
127 microstructure is related to poorer cognitive abilities, especially processing speed and memory deficits [23], by indicating that this
128 'damage-related impairment' is established early, and therefore WM microstructure is a potential biomarker to predict later

29 impairment. Both preclinical and patient studies suggest a loss of both GM and WM volume, and failure of normal WM gain in
30 pediatric brain tumour survivors [16]. There are multiple mechanisms of WM damage; hydrocephalous having direct neurotoxic
31 effects on periventricular WM due to decreased perfusion and oedema [70] or intragenic effect of adjunct therapy (chemo and
32 radiotherapy) as measurable by reduced volume and alterations to microstructural properties and failure of expected WM
33 development [51, 71]. WM damage is likely non-transient; for instance, in non-irradiated patients 15 years after diagnosis, FA
34 measures are reduced and are associated with impaired cognitive flexibility [72]. What is apparent is that, across treatment and
35 disease effects, the subsequent WM injury is relevant to poor outcomes, across emotion, cognition, and behaviour [14, 51, 73].

36 **Specific issues with current research**

37 *Limited longitudinal studies*

38 The biggest limitation of the current research field is the lack of longitudinal research answering this research question. Whilst
39 there have been multiple studies understanding the contemporaneous neuroanatomical substrates of poor neuropsychological
40 outcomes in pediatric brain tumours, from acutely post treatment to very long-term survivors, these have not translated into
41 similarly large body of work understanding long-term risk (as highlighted by our findings) of cognitive morbidity. Further
42 longitudinal research is needed to assess whether the contemporaneous neuroanatomical substrates of long-term impairment are in
43 fact predictive in the context of longitudinal studies.

44 These longitudinal studies would also provide an opportunity to disentangle the developmental and age-related effects on this
45 prediction-task. For several of the measures highlighted in this review (FA/MD etc.) there are known developmental trajectories
46 [74] which will necessarily interact with disease-related changes. There is also likely to be unique effects of brain insult, across
47 tumour growth, and treatment related injury at different ages, resulting in varying levels of long-term impairments [75]. The field
48 will need to rely upon longitudinal studies (with sufficient sample size/statistical power) that can sufficiently disentangle these
49 interactions.

50 *Study Variables: Timing*

51 The current systematic review includes studies that use MRI from any point in the disease course. The timepoint of the MRI used
52 for the purposes of prediction in the reviewed studies were most commonly post some form of treatment (surgical or post radiation
53 therapy, e.g. [60] and [59] respectively) other than 57 which included MRI during treatment. Given the limited research
54 available, this was done to assess the entire literature, but results from different timepoints in the disease to conduct prediction will
55 undoubtedly have varying interpretations. For instance, post-treatment MRI may identify insult-related factors which are related to
56 later decline – as demonstrated by the study by Wang and colleagues [60]. Pre-treatment MRI may allow us to identify specific
57 vulnerabilities to the longer-term neurocognitive effects – for instance Zheng and colleagues [76] propose that functional network
58 plasticity pre-treatment may mediate the impact of surgery on later cognitive ability. However, any MRI timepoint is likely to
59 capture a mixture of these two influences, vulnerability, and insult factors, which may contribute towards prediction.

50 Overall, there is no consensus on the optimal timing of MR imaging to use for predictive purposes. Selection of which MRI is
51 likely to be most predictive (in terms of reliability, accuracy etc.) will not be trivial for future research. We propose that for future
52 research, selection of MRI timepoints with which to test predictive validity should be guided by two principals – a) clinical need,
53 and b) evidence-based theoretical grounds. For instance, in terms of clinical need, if the most useful purpose of these models is to
54 aid/supplement treatment management decisions, then an early, pre-treatment MRI will be necessary. In terms of guiding MRI
55 timing based upon existing evidence a strong example of this is the study by Wang and colleagues [60] which suggests there is a
56 treatment related ‘injury’ which mediates radiotherapy—related working memory impairment, suggesting post treatment MRI
57 would have benefit. Timing is an even greater consideration in this patient group compared to adult brain tumour patients due to
58 the likely interaction also with ongoing brain development over time for these patients.

59 These children undergo MRI scanning at a number of timepoints in their disease course (e.g. diagnostic imaging, pre- and post-
60 surgical evaluation, progression monitoring etc), and so there is significant data for potential retrospective studies to investigate
61 effect of MRI timing on prediction. Direct comparisons between models using MRI from different timepoints will be meaningful
62 to understand variation on predictive validity over time, and further inform designs for prospective predictive studies.

73 Timing of neuropsychological assessment is also not to be overlooked. To develop predictive models, a given endpoint will need
74 to be set (for instance a given number of years post diagnosis). Overall neurocognitive trajectory is “idiosyncratic” over time, with
75 longitudinal studies suggesting an injury-related early impact, followed by a decline or failure to meet the normal developmental
76 trajectory and potential long-term plateauing [11, 18]. Therefore, the endpoint of interest, may also inform the timing of MRI
77 which may be more predictive of longer-term outcomes.

78 *Added Value of MRI*

79 A major limitation of the current state of the research literature in this field is that the added value of MRI in prediction has not
80 been established, above and beyond existing approaches. No reviewed studies assessed existing risk factors in a multivariate

31 analysis to test the relative contributions, and therefore added value, of early MRI in predicting future neurobehavioral
32 morbidities. However, Partanen et. al. reported that none of the medical or treatment variables that they tested predicted change in
33 IQ scores over time [58]. This is despite these medical variables (Neurological Predictor Scale and presence of cerebellar mutism
34 syndrome) predicting acute/contemporaneous neuropsychology outcomes, and MRI-derived measures of baseline WM injury
35 being significantly related with outcomes [58]. This is limited evidence to support the incremental validity of MRI as a predictor
36 of long-term outcomes. Future studies should ensure to test for unique and additional predictive power offered by quantitative
37 MRI variables

38 Study Variables: Approach to ROIs

39 Across the studies reviewed here two conducted analyses in regions-of-interest (ROIs) directly related to sites of brain insult in
40 these patients [57, 58], one in ROIs related to the cognitive comorbidity under investigation [59], and only one investigating
41 characteristics of the lesion itself [61]. This does not consider how the wider brain network may be influenced by the brain
42 tumour, and this information may explain/predict additional variance in outcomes. For instance, in paediatric neurological
43 disorders/syndromes, differences in brain morphometry or connectivity have been found beyond the site of pathology (i.e.
44 paediatric epilepsy [77]) or in the absence of frank pathology (i.e. mild paediatric TBI [78], MRI-negative epilepsy [79]).
45 Disconnectome symptom mapping, shows that non-homologous lesions to the same brain network can generate the same
46 cognitive sequelae in terms of deficits. [80]. Many compensatory and ‘rerouting’ models of functional brain activity post injury
47 suggest that regions beyond the focal lesion may explain some sparing of cognitive abilities (another important factor in predicting
48 endpoint neurobehavioral morbidities). These findings all show that disparate, diffuse, and non-lesioned changes to the brain,
49 including tissue which may be typically thought of as ‘spared’, could also explain variance in neurobehavioral morbidities.
50 Connectivity approaches to MRI have shown utility in contemporaneous measurements of MRI and neuropsychology [81, 82].
51 These neurobiological effects of injury beyond the focal lesion may provide further prognostic information towards the aim of a
52 predictive model, however, to test a greater number of regions larger sample sizes will be necessary to accurately estimate
53 statistical models across many more ROIs. This highlights one of the key challenges for future studies in this field being data
54 collection.

55 **Recommendations for future research**

56 Beyond the apparent requirement for more research studies in this field, there are specific recommendations that should guide
57 future endeavours. In many cases, due to the rarity of disease, multinational and multicentre analyses will be needed to achieve
58 the sample sizes necessary to definitively address some of the issues in this review. To do so, a level of harmonisation amongst
59 research groups in terms of data collection is necessary to facilitate combining of cohorts. For instance, adhering to similar
60 imaging protocols (following guidelines for advanced MRI in pediatric CNS such as those proposed by the European Society of
61 Pediatric Oncology (SIOPE) [83]). Harmonisation will not only allow integration of multiple datasets, but potentially reduce
62 biases in measurements caused by differences in MRI acquisition protocols.

63 Additionally, harmonisation of neurocognitive assessment will also facilitate data aggregation. In the absence of a common
64 outcome measure for these children (for instance a common data elements set as proposed by the National Institute of
65 Neurological Disorders and Stroke (NINDS) for other neurological disease [84]) broad composite measures should be used that
66 can capture multiple aspects of the neurocognitive morbidity experienced by these patients (for example the Wechsler Intelligence
67 Scale for Children [46] or the NIH Toolbox Cognition Battery [85]). Neurocognitive assessment protocols are being developed for
68 specific tumour groups (for instance in childhood ependymomas [86]) which will provide practical approaches to “strongly
69 support the routine incorporation of neuropsychology assessments as key outcomes” to “facilitate successful global
70 collaborations” [87]. These should be adopted wherever possible.

71 To facilitate future reviews such as this, and more importantly meta-analyses of said future research, greater reporting
72 expectations should be placed on researchers – given the current review highlighted this to be a key weakness in existing research.
73 Emphasis should be on using reporting guidelines, and quality assessment checklists (such as the REMARK checklist used in the
74 current review [47], or the tools provided by the EQUATOR (Enhancing the QUALity and Transparency Of health Research)
75 Network [88] such as the TRIPOD tool [89]). Transparent and full reporting will allow better assessment of the literature across
76 the field. These recommendations will help facilitate the important goals of this research, hopefully leading to greater clinical
77 impact.

78 **Limitations of Review**

79 It should be noted that, despite an extensive search, no study explicitly investigated the research question of whether MRI could
80 be used for long term prediction of neurocognitive outcomes in pediatric brain tumour patients. Described studies were reviewed
81 here due to non-primary analyses which fulfilled inclusion criteria, and therefore it may be the case that other studies with such
82 analyses may have been missed in the review process (for instance if these secondary analyses were not mentioned in the
83 abstract). To address this, we erred on the side of caution in reviewing abstracts, using full-text review as a method to identify
84 these relevant secondary analyses.

35 **Conclusion**

36 As early as 2008, it was proposed that to truly balance the aggressiveness of treatment for childhood CNS tumours, against the
37 relative quality of life due to cognitive impairment, an important factor is knowing the likelihood of any one individual
38 experiencing neurocognitive impairment [13]. This individualised risk is key in purported models of monitoring and managing of
39 neurocognitive functioning in children with brain tumours [90]. There has also been significant work in the field of pediatric brain
40 tumours proposing developmental cognitive neuroscience models of late effects in survivors [13, 23, 91, 92]. These models, built
41 on contemporaneous measures of cognition and brain development, alongside cross-sectional data, are inherently limited.
42 Knowing individualised risk of long-term cognitive morbidity ahead of time would have significant clinical impact; to inform
43 clinical management, prioritise resources/support, and reduce uncertainty for families. Overall, there exists plenty clinical
44 reasoning to prompt scientific enthusiasm and attention for this topic.

45 However, despite these early calls for prediction, and models with which to guide these predictive studies, this systematic review
46 highlights that the number of truly predictive studies (requiring a period between predictive features and long-term outcomes) is
47 still limited. In conclusion, Given the increased number of adult survivors of childhood brain tumours, the poorer long-term
48 cognitive, educational and employment outcomes [10, 14, 15] and the significant burden this represents to patients, families and
49 healthcare, work now needs to be completed to integrate predictive data into these models, which will expand their explanatory
50 value and utility to clinical practice. This will be an important next step in delivering further clinical impact for this patient group.

51 Given the great potential that MRI provides in investigating neurobiological effects of disease and treatment at the individual-
52 level, the plethora of multimodal imaging available in these clinical populations and finally the positive clinical benefit this could
53 offer, there is exciting opportunities for this type of research.

54

55 ***Data Availability***

56 Data extracted from included studies is publicly available and found (in its entirety) in Table 2. Lists of reviewed studied, at each
57 stage of the PRISMA flowchart are available from the authors upon reasonable request.

58 ***Acknowledgments***

59 DGK is funded by a post-doctoral award from Aston University College of Health and Life Sciences, awarded to JN & DGK.

50

51

References

- 52 1. Miller, K.D., L. Nogueira, T. Devasia, A.B. Mariotto, K.R. Yabroff, A. Jemal, J. Kramer, and R.L. Siegel, *Cancer*
53 *treatment and survivorship statistics, 2022*. CA Cancer J Clin, 2022. **72**(5): p. 409-436.
- 54 2. Phillips, S.M., L.S. Padgett, W.M. Leisenring, K.K. Stratton, K. Bishop, K.R. Krull, C.M. Alfano, T.M. Gibson, J.S.
55 de Moor, D.B. Hartigan, G.T. Armstrong, L.L. Robison, J.H. Rowland, K.C. Oeffinger, and A.B. Mariotto,
56 *Survivors of childhood cancer in the United States: prevalence and burden of morbidity*. Cancer Epidemiol
57 Biomarkers Prev, 2015. **24**(4): p. 653-663.
- 58 3. American Cancer Society, *Cancer Facts & Figures 2014*, A.C. Society, Editor. 2014, American Cancer Society:
59 Atlanta.
- 60 4. Ward, E., C. DeSantis, A. Robbins, B. Kohler, and A. Jemal, *Childhood and adolescent cancer statistics, 2014*.
61 CA Cancer J Clin, 2014. **64**(2): p. 83-103.
- 62 5. Tabash, M.A., *Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in*
63 *the United States; SEER-based analysis*. J Neurol Sci, 2019. **400**: p. 148-152.
- 64 6. Ramaswamy, V. and M.D. Taylor, *Medulloblastoma: From Myth to Molecular*. J Clin Oncol, 2017. **35**(21): p.
65 2355-2363.
- 66 7. Gatta, G., G. Zigon, R. Capocaccia, J.W. Coebergh, E. Desandes, P. Kaatsch, G. Pastore, R. Peris-Bonet, C.A.
67 Stiller, and E.W. Group, *Survival of European children and young adults with cancer diagnosed 1995-2002*.
68 Eur J Cancer, 2009. **45**(6): p. 992-1005.
- 69 8. Prevention, C.f.D.C., *Declines in cancer death rates among children and adolescents in the United States,*
70 *1999-2014*. 2016.
- 71 9. Wang, Y., A.P.Y. Liu, T.M. Lee, W.H.S. Wong, D.Y.T. Fong, L.K. Leung, M.M.K. Shing, D.T. Ku, G.C. Chan, and
72 W.W. Tso, *Neurobehavioral Impairment in Pediatric Brain Tumor Survivors: A Meta-Analysis*. Cancers (Basel),
73 2022. **14**(13).
- 74 10. Maddrey, A.M., J.A. Bergeron, E.R. Lombardo, N.K. McDonald, A.F. Mulne, P.D. Barenberg, and D.C. Bowers,
75 *Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma*. J
76 Neurooncol, 2005. **72**(3): p. 245-53.
- 77 11. Tønning Olsson, I., J. Lundgren, L. Hjorth, P. Munck Af Rosenschold, A. Hammar, and S. Perrin,
78 *Neurocognitive development after pediatric brain tumor - a longitudinal, retrospective cohort study*. Child
79 Neuropsychol, 2024. **30**(1): p. 22-44.
- 80 12. Palmer, S.L., O. Goloubeva, W.E. Reddick, J.O. Glass, A. Gajjar, L. Kun, T.E. Merchant, and R.K. Mulhern,
81 *Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis*.
82 Journal of Clinical Oncology, 2001. **19**(8): p. 2302-2308.
- 83 13. Askins, M.A. and B.D. Moore, 3rd, *Preventing neurocognitive late effects in childhood cancer survivors*. J Child
84 Neurol, 2008. **23**(10): p. 1160-71.
- 85 14. Lassaletta, A., E. Bouffet, D. Mabbott, and A.V. Kulkarni, *Functional and neuropsychological late outcomes in*
86 *posterior fossa tumors in children*. Childs Nerv Syst, 2015. **31**(10): p. 1877-90.
- 87 15. Devine, K.A., S. Christen, R.L. Mulder, M.C. Brown, L.M. Ingerski, L. Mader, E.J. Potter, C. Sleurs, A.S. Viola, S.
88 Waern, L.S. Constine, M.M. Hudson, L.C.M. Kremer, R. Skinner, G. Michel, J. Gilleland Marchak, F.S.M.
89 Schulte, and G. International Guidelines Harmonization Group Psychological Late Effects, *Recommendations*
90 *for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young*
91 *adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization*
92 *Group*. Cancer, 2022. **128**(13): p. 2405-2419.
- 93 16. Al Dahhan, N.Z., E. Cox, B.J. Nieman, and D.J. Mabbott, *Cross-translational models of late-onset cognitive*
94 *sequelae and their treatment in pediatric brain tumor survivors*. Neuron, 2022. **110**(14): p. 2215-2241.
- 95 17. Hardy, K.K., M.M. Hudson, and K.R. Krull, *Life-Altering Consequences of Neurocognitive Impairment in*
96 *Survivors of Pediatric Cancer*. J Clin Oncol, 2021. **39**(16): p. 1693-1695.
- 97 18. Willard, V.W., K.S. Berlin, H.M. Conklin, and T.E. Merchant, *Trajectories of psychosocial and cognitive*
98 *functioning in pediatric patients with brain tumors treated with radiation therapy*. Neuro Oncol, 2019. **21**(5):
99 p. 678-685.
- 100 19. Sharkey, C.M., L.L. Mullins, A.H. Clawson, A. Gioia, M.A.W. Hawkins, J.M. Chaney, K.S. Walsh, and K.K. Hardy,
101 *Assessing neuropsychological phenotypes of pediatric brain tumor survivors*. Psychooncology, 2021. **30**(8): p.
102 1366-1374.

- 13 20. Major, N., N.A. Patel, J. Bennett, E. Novakovic, D. Poloni, M. Abraham, N.J. Brown, J.L. Gendreau, R.
14 Sahyouni, and J. Loya, *The Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of Post-*
15 *Radiotherapy Neurocognitive Decline and Outcomes*. *J Pers Med*, 2022. **12**(7).
- 16 21. Ajithkumar, T., S. Price, G. Horan, A. Burke, and S. Jefferies, *Prevention of radiotherapy-induced*
17 *neurocognitive dysfunction in survivors of paediatric brain tumours: the potential role of modern imaging*
18 *and radiotherapy techniques*. *Lancet Oncol*, 2017. **18**(2): p. e91-e100.
- 19 22. Peterson, R.K. and T.Z. King, *A systemic review of pediatric neuropsychological outcomes with proton versus*
20 *photon radiation therapy: A call for equity in access to treatment*. *J Int Neuropsychol Soc*, 2022: p. 1-14.
- 21 23. Wauters, M., A. Uyttebroeck, L. De Waele, C. Sleurs, and S. Jacobs, *Neuroimaging Biomarkers and*
22 *Neurocognitive Outcomes in Pediatric Medulloblastoma Patients: a Systematic Review*. *Cerebellum*, 2021.
23 **20**(3): p. 462-480.
- 24 24. Oyefiade, A., I. Paltin, C.R. De Luca, K.K. Hardy, D.R. Grosshans, M. Chintagumpala, D.J. Mabbott, and L.S.
25 Kahalley, *Cognitive Risk in Survivors of Pediatric Brain Tumors*. *J Clin Oncol*, 2021. **39**(16): p. 1718-1726.
- 26 25. Palmer, S.L., *Neurodevelopmental impact on children treated for medulloblastoma: a review and proposed*
27 *conceptual model*. *Dev Disabil Res Rev*, 2008. **14**(3): p. 203-10.
- 28 26. Wolfe, K.R., A. Madan-Swain, and R.K. Kana, *Executive dysfunction in pediatric posterior fossa tumor*
29 *survivors: a systematic literature review of neurocognitive deficits and interventions*. *Dev Neuropsychol*,
30 2012. **37**(2): p. 153-75.
- 31 27. King, T.Z., A.S. Ailion, M.E. Fox, and S.M. Hufstetler, *Neurodevelopmental model of long-term outcomes of*
32 *adult survivors of childhood brain tumors*. *Child Neuropsychol*, 2019. **25**(1): p. 1-21.
- 33 28. Marusak, H.A., A.S. Iadipalo, F.W. Harper, F. Elrahal, J.W. Taub, E. Goldberg, and C.A. Rabinak,
34 *Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity*
35 *framework to understanding cognitive, behavioral, and emotional outcomes*. *Neuropsychol Rev*, 2018. **28**(2):
36 p. 123-175.
- 37 29. King, A.A., K. Seidel, C. Di, W.M. Leisenring, S.M. Perkins, K.R. Krull, C.A. Sklar, D.M. Green, G.T. Armstrong,
38 L.K. Zeltzer, E. Wells, M. Stovall, N.J. Ullrich, K.C. Oeffinger, L.L. Robison, and R.J. Packer, *Long-term*
39 *neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report*
40 *from the Childhood Cancer Survivor Study*. *Neuro Oncol*, 2017. **19**(5): p. 689-698.
- 41 30. de Ruiter, M.A., R. van Mourik, A.Y. Schouten-van Meeteren, M.A. Grootenhuis, and J. Oosterlaan,
42 *Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis*. *Dev Med Child*
43 *Neurol*, 2013. **55**(5): p. 408-17.
- 44 31. Nathan, P.C., S.K. Patel, K. Dilley, R. Goldsby, J. Harvey, C. Jacobsen, N. Kadan-Lottick, K. McKinley, A.K.
45 Millham, I. Moore, M.F. Okcu, C.L. Woodman, P. Brouwers, F.D. Armstrong, and C. Children's Oncology
46 Group Long-term Follow-up Guidelines Task Force on Neurocognitive/Behavioral Complications After
47 Childhood, *Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in*
48 *survivors of childhood cancer: a report from the Children's Oncology Group*. *Arch Pediatr Adolesc Med*, 2007.
49 **161**(8): p. 798-806.
- 50 32. Krull, K.R., S. Minoshima, M. Edelmann, B. Morris, N.D. Sabin, T.M. Brinkman, G.T. Armstrong, L.L. Robison,
51 M.M. Hudson, and B. Shulkin, *Regional brain glucose metabolism and neurocognitive function in adult*
52 *survivors of childhood cancer treated with cranial radiation*. *J Nucl Med*, 2014. **55**(11): p. 1805-10.
- 53 33. Carpentieri, S.C., D.P. Waber, S.L. Pomeroy, R.M. Scott, L.C. Goumnerova, M.W. Kieran, A.L. Billett, and N.J.
54 Tarbell, *Neuropsychological functioning after surgery in children treated for brain tumor*. *Neurosurgery*,
55 2003. **52**(6): p. 1348-56; discussion 1356-7.
- 56 34. Taiwo, Z., S. Na, and T.Z. King, *The Neurological Predictor Scale: A predictive tool for long-term core cognitive*
57 *outcomes in survivors of childhood brain tumors*. *Pediatr Blood Cancer*, 2017. **64**(1): p. 172-179.
- 58 35. Levitch, C.F., A.A. Holland, J. Bledsoe, S.Y. Kim, M. Barnett, S. Ramjan, and S.A. Sands, *Comparison of*
59 *neuropsychological functioning in pediatric posterior fossa tumor survivors: Medulloblastoma, low-grade*
60 *astrocytoma, and healthy controls*. *Pediatr Blood Cancer*, 2022. **69**(2): p. e29491.
- 51 36. Micklewright, J.L., T.Z. King, R.D. Morris, and N. Krawiecki, *Quantifying pediatric neuro-oncology risk factors:*
52 *development of the neurological predictor scale*. *J Child Neurol*, 2008. **23**(4): p. 455-8.
- 53 37. Papazoglou, A., T.Z. King, R.D. Morris, and N. Krawiecki, *Parent report of attention problems predicts later*
54 *adaptive functioning in children with brain tumors*. *Child Neuropsychol*, 2009. **15**(1): p. 40-52.
- 55 38. King, T.Z. and S. Na, *Cumulative neurological factors associated with long-term outcomes in adult survivors of*
56 *childhood brain tumors*. *Child Neuropsychol*, 2016. **22**(6): p. 748-60.

- 57 39. Kautiainen, R.J., S.D. Na, and T.Z. King, *Neurological predictor scale is associated with academic achievement*
58 *outcomes in long-term survivors of childhood brain tumors.* J Neurooncol, 2019. **142**(1): p. 193-201.
- 59 40. Bae, D., V.V. Mlc, and C.E. Catsman-Berrevoets, *Preoperative prediction of postoperative cerebellar mutism*
60 *syndrome. Validation of existing MRI models and proposal of the new Rotterdam pCMS prediction model.*
61 Childs Nerv Syst, 2020. **36**(7): p. 1471-1480.
- 62 41. Kesler, S.R., C. Sleurs, B.C. McDonald, S. Deprez, E. van der Plas, and B.J. Nieman, *Brain Imaging in Pediatric*
63 *Cancer Survivors: Correlates of Cognitive Impairment.* J Clin Oncol, 2021. **39**(16): p. 1775-1785.
- 64 42. Baker, S. and Y. Kandasamy, *Machine learning for understanding and predicting neurodevelopmental*
65 *outcomes in premature infants: a systematic review.* Pediatr Res, 2022: p. 1-7.
- 66 43. Li, X., X. Wang, L. Su, X. Hu, and Y. Han, *Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a*
67 *Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive*
68 *impairment in individuals with subjective cognitive decline.* BMJ Open, 2019. **9**(7): p. e028188.
- 69 44. Page, M.J., J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff,
70 E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hrobjartsson, M.M. Lalu, T. Li, E.W. Loder, E.
71 Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. Welch, P. Whiting,
72 and D. Moher, *The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.* Syst Rev,
73 2021. **10**(1): p. 89.
- 74 45. Ostrom, Q.T., G. Cioffi, K. Waite, C. Kruchko, and J.S.J.N.-o. Barnholtz-Sloan, *CBTRUS statistical report:*
75 *primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018.* 2021.
76 **23**(Supplement_3): p. iii1-iii105.
- 77 46. Wechsler, D., *Wechsler Intelligence Scale for Children (5th ed.).* . 2014, San Antonio: Texas: Pearson.
- 78 47. McShane, L.M., D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark, *Reporting recommendations*
79 *for tumor marker prognostic studies (REMARK).* Journal of the National Cancer Institute, 2005. **97**(16): p.
80 1180-1184.
- 81 48. Sauerbrei, W., S.E. Taube, L.M. McShane, M.M. Cavenagh, and D.G. Altman, *Reporting Recommendations for*
82 *Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.* J Natl Cancer Inst,
83 2018. **110**(8): p. 803-811.
- 84 49. Aukema, E.J., M.W. Caan, N. Oudhuis, C.B. Majoie, F.M. Vos, L. Reneman, B.F. Last, M.A. Grootenhuys, and
85 A.Y. Schouten-van Meeteren, *White matter fractional anisotropy correlates with speed of processing and*
86 *motor speed in young childhood cancer survivors.* Int J Radiat Oncol Biol Phys, 2009. **74**(3): p. 837-43.
- 87 50. Mulhern, R.K., S.L. Palmer, W.E. Reddick, J.O. Glass, L.E. Kun, J. Taylor, J. Langston, and A. Gajjar, *Risks of*
88 *young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss.* J
89 Clin Oncol, 2001. **19**(2): p. 472-9.
- 90 51. Reddick, W.E., D.J. Taghipour, J.O. Glass, J. Ashford, X.P. Xiong, S.J. Wu, M. Bonner, R.B. Khan, and H.M.
91 Conklin, *Prognostic Factors that Increase the Risk for Reduced White Matter Volumes and Deficits in*
92 *Attention and Learning for Survivors of Childhood Cancers.* Pediatric Blood & Cancer, 2014. **61**(6): p. 1074-
93 1079.
- 94 52. Tso, W.W.Y., E.S.K. Hui, T.M.C. Lee, A.P.Y. Liu, P. Ip, V. Vardhanabhuti, K.K.F. Cheng, D.Y.T. Fong, D.H.F.
95 Chang, F.K.W. Ho, K.M. Yip, D.T.L. Ku, D.K.L. Cheuk, C.W. Luk, M.K. Shing, L.K. Leung, P.L. Khong, and G.C.
96 Chan, *Brain Microstructural Changes Associated With Neurocognitive Outcome in Intracranial Germ Cell*
97 *Tumor Survivors.* Front Oncol, 2021. **11**: p. 573798.
- 98 53. Seitzman, B.A., H. Anandarajah, A. Dworetzky, A. McMichael, R.S. Coalson, A.M. Agamah, C. Jiang, H. Gu, D.L.
99 Barbour, B.L. Schlaggar, D.D. Limbrick, J.B. Rubin, J.S. Shimony, and S.M. Perkins, *Cognitive deficits and*
100 *altered functional brain network organization in pediatric brain tumor patients.* Brain Imaging and Behavior,
101 2023. **17**(6): p. 689-701.
- 102 54. Dorfer, C., T. Pletschko, R. Seiger, M. Chocholous, G. Kasprian, J. Krajnik, K. Roessler, K. Kollndorfer, V.
103 Schöpf, U. Leiss, I. Slavc, D. Prayer, R. Lanzenberger, and T. Czech, *Impact of childhood cerebellar tumor*
104 *surgery on cognition revealed by precuneus hyperconnectivity.* Neuro-Oncology Advances, 2022. **4**(1).
- 105 55. Zheng, W., X. Guan, X. Zhang, and J. Gong, *Early recovery of cognition and brain plasticity after surgery in*
106 *children with low-grade frontal lobe tumors.* Front Pediatr, 2023. **11**: p. 1127098.
- 107 56. Kline, C., S. Stoller, L. Byer, D. Samuel, J.M. Lupo, M.A. Morrison, A.M. Rauschecker, P. Nedelec, W. Faig, D.B.
108 Dubal, H.J. Fullerton, and S. Mueller, *An Integrated Analysis of Clinical, Genomic, and Imaging Features*
109 *Reveals Predictors of Neurocognitive Outcomes in a Longitudinal Cohort of Pediatric Cancer Survivors,*
110 *Enriched with CNS Tumors (Rad ART Pro).* Front Oncol, 2022. **12**: p. 874317.

- 21 57. Liguoro, I., E. Passone, T. Zilli, M. Maieron, M.C. De Colle, M. Skrap, V. Dolcemascolo, G. Sommariva, P. Cogo,
22 and B. Tomasino, *Possible association between the integrity of cerebellar pathways and neurocognitive*
23 *performance in children with posterior fossa tumors*. *Pediatr Blood Cancer*, 2020. **67**(9): p. e28538.
- 24 58. Partanen, M., E. Bouffet, S. Laughlin, D. Strother, J. Hukin, J. Skocic, K. Szulc-Lerch, and D.J. Mabbott, *Early*
25 *changes in white matter predict intellectual outcome in children treated for posterior fossa tumors*.
26 *Neuroimage Clin*, 2018. **20**: p. 697-704.
- 27 59. Riggs, L., E. Bouffet, S. Laughlin, N. Laperriere, F. Liu, J. Skocic, N. Scantlebury, F. Wang, N.J. Schoenhoff, D.
28 Strother, J. Hukin, C. Fryer, D. McConnell, and D.J. Mabbott, *Changes to memory structures in children*
29 *treated for posterior fossa tumors*. *J Int Neuropsychol Soc*, 2014. **20**(2): p. 168-80.
- 30 60. Wang, J.X., Y. Li, W.E. Reddick, H.M. Conklin, J.O. Glass, A. Onar-Thomas, A. Gajjar, C. Cheng, and Z.H. Lu, *A*
31 *high-dimensional mediation model for a neuroimaging mediator: Integrating clinical, neuroimaging, and*
32 *neurocognitive data to mitigate late effects in pediatric cancer*. *Biometrics*, 2023. **79**(3): p. 2430-2443.
- 33 61. Zilli, T., V. Dolcemascolo, E. Passone, M. Maieron, M.C. De Colle, M. Skrap, T. Lus, I. Liguoro, M. Venchiarutti,
34 P. Cogo, and B. Tomasino, *A multimodal approach to the study of children treated for posterior fossa tumor:*
35 *A review of the literature and a pilot study*. *Clin Neurol Neurosurg*, 2021. **207**: p. 106819.
- 36 62. Rey-Casserly, C. and T.J.C.o.i.p. Diver, *Late effects of pediatric brain tumors*. 2019. **31**(6): p. 789-796.
- 37 63. Alemany, M., R. Velasco, M. Simó, and J.J.N.-O.P. Bruna, *Late effects of cancer treatment: consequences for*
38 *long-term brain cancer survivors*. 2021. **8**(1): p. 18-30.
- 39 64. Horska, A., A. Laclair, M. Mohamed, C.T. Wells, T. McNutt, K.J. Cohen, M. Wharam, E.M. Mahone, and W.
40 Kates, *Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for*
41 *brain tumors and leukemia*. *AJNR Am J Neuroradiol*, 2010. **31**(8): p. 1430-7.
- 42 65. Hoang, D.H., A. Pagnier, K. Guichardet, F. Dubois-Teklali, I. Schiff, G. Lyard, E. Cousin, and A. Krainik,
43 *Cognitive disorders in pediatric medulloblastoma: what neuroimaging has to offer*. *J Neurosurg Pediatr*,
44 2014. **14**(2): p. 136-44.
- 45 66. Badura, A., J.L. Verpeut, J.W. Metzger, T.D. Pereira, T.J. Pisano, B. Deverett, D.E. Bakshinskaya, and S.S.
46 Wang, *Normal cognitive and social development require posterior cerebellar activity*. *Elife*, 2018. **7**.
- 47 67. Clark, S.V., E.S. Semmel, H.A. Aleksonis, S.N. Steinberg, and T.Z. King, *Cerebellar-Subcortical-Cortical Systems*
48 *as Modulators of Cognitive Functions*. *Neuropsychol Rev*, 2021. **31**(3): p. 422-446.
- 49 68. Schmahmann, J.D., *The cerebellum and cognition*. *Neurosci Lett*, 2019. **688**: p. 62-75.
- 50 69. Gomes, C.A., K.M. Steiner, N. Ludolph, T. Spisak, T.M. Ernst, O. Mueller, S.L. Goricke, F. Labrenz, W. Ilg, N.
51 Axmacher, and D. Timmann, *Resection of cerebellar tumours causes widespread and functionally relevant*
52 *white matter impairments*. *Hum Brain Mapp*, 2021. **42**(6): p. 1641-1656.
- 53 70. Moberget, T., S. Andersson, T. Lundar, B.J. Due-Tonnessen, A. Heldal, T. Endestad, and L.T. Westlye, *Long-*
54 *term supratentorial brain structure and cognitive function following cerebellar tumour resections in*
55 *childhood*. *Neuropsychologia*, 2015. **69**: p. 218-31.
- 56 71. Witzmann, K., F. Raschke, and E.G.C. Troost, *MR Image Changes of Normal-Appearing Brain Tissue after*
57 *Radiotherapy*. *Cancers (Basel)*, 2021. **13**(7).
- 58 72. Billiet, T., I. Elens, C. Sleurs, A. Uyttebroeck, R. D'Hooge, J. Lemiere, and S. Deprez, *Brain Connectivity and*
59 *Cognitive Flexibility in Nonirradiated Adult Survivors of Childhood Leukemia*. *J Natl Cancer Inst*, 2018. **110**(8):
60 p. 905-913.
- 61 73. Raghobar, K.P., E.M. Mahone, K.O. Yeates, K.M. Cecil, M. Makola, and M.D. Ris, *Working memory and*
62 *attention in pediatric brain tumor patients treated with and without radiation therapy*. *Child Neuropsychol*,
63 2017. **23**(6): p. 642-654.
- 64 74. Krogsrud, S.K., A.M. Fjell, C.K. Tamnes, H. Grydeland, L. Mork, P. Due-Tonnessen, A. Bjornerud, C. Sampaio-
65 Baptista, J. Andersson, H. Johansen-Berg, and K.B. Walhovd, *Changes in white matter microstructure in the*
66 *developing brain--A longitudinal diffusion tensor imaging study of children from 4 to 11years of age*.
67 *Neuroimage*, 2016. **124**(Pt A): p. 473-486.
- 68 75. Jones, R.M. and S.S. Pattwell, *Future considerations for pediatric cancer survivorship: Translational*
69 *perspectives from developmental neuroscience*. *Dev Cogn Neurosci*, 2019. **38**: p. 100657.
- 70 76. Zheng, W.J., X.Y. Guan, H.N. Zhai, and J. Gong, *Altered functional connectivity in default mode network*
71 *maintains attention task performance in school-age children with frontal lobe tumor*. *Appl Neuropsychol*
72 *Child*, 2024: p. 1-11.
- 73 77. Boutzoukas, E.M., J. Crutcher, E. Somoza, L.N. Sepeta, X. You, W.D. Gaillard, G.L. Wallace, and M.M. Berl,
74 *Cortical thickness in childhood left focal epilepsy: Thinning beyond the seizure focus*. *Epilepsy Behav*, 2020.
75 **102**: p. 106825.

- 76 78. King, D.J., K.R. Ellis, S. Seri, and A.G. Wood, *A systematic review of cross-sectional differences and*
77 *longitudinal changes to the morphometry of the brain following paediatric traumatic brain injury.*
78 *Neuroimage Clin*, 2019. **23**: p. 101844.
- 79 79. Zelko, F.A., H.R. Pardoe, S.R. Blackstone, G.D. Jackson, and A.T. Berg, *Regional brain volumes and cognition in*
30 *childhood epilepsy: does size really matter?* *Epilepsy Res*, 2014. **108**(4): p. 692-700.
- 31 80. Foulon, C., L. Cerliani, S. Kinkingnéhun, R. Levy, C. Rosso, M. Urbanski, E. Volle, and M. Thiebaut de Schotten,
32 *Advanced lesion symptom mapping analyses and implementation as BCBtoolkit.* *Gigascience*, 2018. **7**(3): p.
33 1-17.
- 34 81. Sleurs, C., J. Blommaert, D. Batalle, M. Verly, S. Sunaert, R. Peeters, J. Lemiere, A. Uyttebroeck, and S.
35 Deprez, *Cortical thinning and altered functional brain coherence in survivors of childhood sarcoma.* *Brain*
36 *Imaging Behav*, 2021. **15**(2): p. 677-688.
- 37 82. Sleurs, C., S. Jacobs, S.J. Counsell, D. Christiaens, J.D. Tournier, S. Sunaert, K. Van Beek, A. Uyttebroeck, S.
38 Deprez, D. Batalle, and J. Lemiere, *Brain network hubs and cognitive performance of survivors of childhood*
39 *infratentorial tumors.* *Radiother Oncol*, 2021. **161**: p. 118-125.
- 30 83. Avula, S., A. Peet, G. Morana, P. Morgan, M. Warmuth-Metz, T. Jaspan, and G. European Society for
31 *Paediatric Oncology -Brain Tumour Imaging, European Society for Paediatric Oncology (SIOPE) MRI guidelines*
32 *for imaging patients with central nervous system tumours.* *Childs Nerv Syst*, 2021. **37**(8): p. 2497-2508.
- 33 84. Grinnon, S.T., K. Miller, J.R. Marler, Y. Lu, A. Stout, J. Odenkirchen, and S. Kunitz, *National Institute of*
34 *Neurological Disorders and Stroke Common Data Element Project - approach and methods.* *Clin Trials*, 2012.
35 **9**(3): p. 322-9.
- 36 85. Akshoomoff, N., J.L. Beaumont, P.J. Bauer, S.S. Dikmen, R.C. Gershon, D. Mungas, J. Slotkin, D. Tulskey, S.
37 Weintraub, P.D. Zelazo, and R.K. Heaton, *VIII. NIH Toolbox Cognition Battery (CB): composite scores of*
38 *crystallized, fluid, and overall cognition.* *Monogr Soc Res Child Dev*, 2013. **78**(4): p. 119-32.
- 39 86. Thomas, S., D. Reynolds, M. Morrall, J. Limond, M. Chevigard, G. Calaminus, G. Poggi, E. Bennett, D.
40 Frappaz, D. Slade, J. Gautier, P. McQuilton, M. Massimino, and R. Grundy, *The European Society of Paediatric*
41 *Oncology Ependymoma-II program Core-Plus model: Development and initial implementation of a cognitive*
42 *test protocol for an international brain tumour trial.* *Eur J Paediatr Neurol*, 2019. **23**(4): p. 560-570.
- 43 87. Dorris, L., E. Molinari, and D. Murphy, *Focusing on cognitive morbidity in childhood brain tumours.* *Eur J*
44 *Paediatr Neurol*, 2019. **23**(4): p. 544-545.
- 45 88. *The EQUATOR (Enhancing the QUALity and Transparency Of health Research) Network.* 2024.
- 46 89. *TRIPOD Statement.* 2023 [cited 2023; Available from: <https://www.tripod-statement.org/>].
- 47 90. Jacola, L.M., M. Partanen, J. Lemiere, M.M. Hudson, and S. Thomas, *Assessment and Monitoring of*
48 *Neurocognitive Function in Pediatric Cancer.* *J Clin Oncol*, 2021. **39**(16): p. 1696-1704.
- 49 91. Ailion, A.S., T.Z. King, L. Wang, M.E. Fox, H. Mao, R.M. Morris, and B. Crosson, *Cerebellar Atrophy in Adult*
50 *Survivors of Childhood Cerebellar Tumor.* *J Int Neuropsychol Soc*, 2016. **22**(5): p. 501-11.
- 51 92. Palmer, S.L., J.O. Glass, Y. Li, R. Ogg, I. Qaddoumi, G.T. Armstrong, K. Wright, C. Wetmore, A. Broniscer, A.
52 Gajjar, and W.E. Reddick, *White matter integrity is associated with cognitive processing in patients treated*
53 *for a posterior fossa brain tumor.* *Neuro Oncol*, 2012. **14**(9): p. 1185-93.